Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study
Blood Purification · 2025
DOI: 10.1159/000549060 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Blood Purification, 2025. Verfasst von Kentaro Ide und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Critical Care Medicine, National Center for Child Health and Development, Setagaya City, Japan, ide-k@ncchd.go.jp. Hauptthemen laut MEDLINE: Guanidines, Antithrombin III, Continuous Renal Replacement Therapy. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Introduction
Premature circuit clotting remains a major limitation of pediatric continuous kidney replacement therapy (CKRT). While anticoagulation with heparin or citrate has been well studied, the risk factors for circuit failure under nafamostat mesylate (NM) use have not been well characterized.
Methods
This retrospective cohort study included pediatric patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Critical Care Medicine, National Center for Child Health and Development, Setagaya City, Japan, ide-k@ncchd.go.jp.
- Division of Critical Care Medicine, National Center for Child Health and Development, Setagaya City, Japan.
- Division of Nephrology and Rheumatology, National Center for Child Health and Development, Setagaya City, Japan.
- Pediatric Intensive Care Unit, Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan.
- Division of Clinical Engineering, National Center for Child Health and Development, Setagaya City, Japan.
Zitieren
APA
Ide, K., Tokuda, Y., Morota, J., Nashiki, E., Nishi, K., Miyaji, M., Shibata, M., & Matsumoto, S. (2025). Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study. Blood Purification. https://doi.org/10.1159/000549060
Vancouver
Ide K, Tokuda Y, Morota J, Nashiki E, Nishi K, Miyaji M, et al. Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study. Blood Purification. 2025. doi:10.1159/000549060
BibTeX
@article{Ide2025,
author = {Ide, Kentaro and Tokuda, Yusuke and Morota, Junichiro and Nashiki, Eisaku and Nishi, Kentaro and Miyaji, Mai and Shibata, Masamichi and Matsumoto, Shotaro},
title = {Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study},
journal = {Blood Purification},
year = {2025},
doi = {10.1159/000549060}
}
EUVIMED